Comparison of Prostate Specific Antigen and Neuropeptide Y Parameters in Patients with Prostate Cancer

Basit Öğe Kaydı
dc.authoridbolat, serkan/0000-0002-8669-8782
dc.contributor.authorOzturk, Abuzer
dc.contributor.authorSaygin, Huseyin
dc.contributor.authorAsdemir, Aydemir
dc.contributor.authorBolat, Serkan
dc.contributor.authorErgin, Ismail Emre
dc.contributor.authorKirac, Emre
dc.contributor.authorKorgali, Esat
dc.date.accessioned2025-05-04T16:45:36Z
dc.date.available2025-05-04T16:45:36Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjective: Prostate cancer is a solid tumor that can be fatal in men. Early detection and proper management are essential for improving outcomes and reducing mortality rates associated with this disease. This study aimed to evaluate the potential of neuropeptide Y (NPY) as a biomarker to enhance the effectiveness of prostate specific antigen (PSA) testing in diagnosing and predicting prostate cancer prognosis. NPY, a well-known sympathetic neurotransmitter, possesses growth-promoting and angiogenic properties in various cell types, including those relevant to prostate cancer. Additionally, NPY has been linked to neuroendocrine differentiation of prostate cancer cells. By comparing the efficacy of PSA testing alone with the addition of NPY, this study aimed to determine whether NPY could offer additional predictive value for prostate cancer progression and prognosis. Materials and Methods: This study involved 90 patients each diagnosed with localized prostate cancer (LPC), metastatic prostate cancer (mPC) at diagnosis, and metastatic castration-resistant prostate cancer (mCRPC) who visited our urology clinic between 2022 and 2023. Blood samples were collected from all participants between 08:00 and 09:00 after a 12 hour fast. In the LPC and mPC groups, samples were collected upon diagnosis, whereas in the mCRPC group, samples were collected upon development of treatment resistance. NPY levels in blood samples were analyzed using enzyme-linked immunosorbent assay method. Serum NPY levels were compared between the LPC, mPC, and mCRPC groups. Results: PSA values were calculated as 12.6 (7.08-32.47) ng/L in the LPC group, 159 (73.1-405.2) ng/L in the mPC group, and 38.33 (18.4-132) ng/L in the mCRPC group, with a statistically significant difference between the groups (p<0.001). The average NPY values were 351.3 +/- 162.7 ng/L in the LPC group, 276.5 +/- 85 ng/L in the mPC group, and 272.13 +/- 94.7 ng/L in the mCRPC group. NPY values were found to be statistically significantly higher in the LPC group (p=0.018). Conclusion: The serum NPY levels were notably elevated in the LPC group compared with the mPC and mCRPC groups. This finding implies a potential association between low NPY levels and mPC as well as mCRPC.
dc.description.sponsorshipSivas Cumhuriyet University office of scientific research projects [T-2022-963]
dc.description.sponsorshipFinancial Disclosure: Financial support was provided by Sivas Cumhuriyet University office of scientific research projects (no: T-2022-963) .
dc.identifier.doi10.4274/uob.galenos.2024.2024.3.1
dc.identifier.endpage83
dc.identifier.issn2147-2270
dc.identifier.issue3
dc.identifier.scopusqualityN/A
dc.identifier.startpage78
dc.identifier.urihttps://doi.org/10.4274/uob.galenos.2024.2024.3.1
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35145
dc.identifier.volume23
dc.identifier.wosWOS:001352311300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofUroonkoloji Bulteni-Bulletin of Urooncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250504
dc.subjectProstate cancer
dc.subjectPSA
dc.subjectNPY
dc.subjectneuropeptide-Y
dc.titleComparison of Prostate Specific Antigen and Neuropeptide Y Parameters in Patients with Prostate Cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu